Bausch + Lomb/$BLCO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bausch + Lomb
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Ticker
$BLCO
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Vaughan, Canada
Employees
13,500
ISIN
CA0717051076
Website
Bausch + Lomb Metrics
BasicAdvanced
$4.3B
-
-$1.03
0.58
-
Price and volume
Market cap
$4.3B
Beta
0.58
52-week high
$21.69
52-week low
$10.45
Average daily volume
649K
Financial strength
Current ratio
1.561
Quick ratio
0.71
Long term debt to equity
74.444
Total debt to equity
75.066
Interest coverage (TTM)
0.33%
Profitability
EBITDA (TTM)
545
Gross margin (TTM)
60.03%
Net profit margin (TTM)
-7.50%
Operating margin (TTM)
2.34%
Effective tax rate (TTM)
-8.95%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
0.53%
Return on equity (TTM)
-5.36%
Valuation
Price to revenue (TTM)
0.88
Price to book
0.67
Price to tangible book (TTM)
-2.61
Price to free cash flow (TTM)
-25.306
Free cash flow yield (TTM)
-3.95%
Free cash flow per share (TTM)
-47.70%
Growth
Revenue change (TTM)
11.94%
Earnings per share change (TTM)
6.69%
3-year revenue growth (CAGR)
8.57%
3-year earnings per share growth (CAGR)
27.15%
Bulls say / Bears say
Bausch + Lomb reported a 9% year-over-year revenue increase in Q4 2024, indicating strong growth across all segments. (stocktitan.net)
The company introduced INFUSE® for Astigmatism daily disposable contact lenses in the U.S., expanding its product portfolio and addressing a significant market need. (stocktitan.net)
Bausch + Lomb launched Blink™ NutriTears®, a clinically proven nutritional supplement for dry eyes, diversifying its offerings and tapping into the growing eye health supplement market. (stocktitan.net)
Morgan Stanley downgraded Bausch + Lomb's stock from 'Overweight' to 'Equal Weight' with a $19.00 target price, reflecting concerns about the company's future performance. (americanbankingnews.com)
The company announced a voluntary recall of certain intraocular lenses due to reports of toxic anterior segment syndrome (TASS), potentially impacting its reputation and sales. (financialcontent.com)
Bausch + Lomb's stock hit a new 12-month low following a disappointing earnings announcement, reporting a net loss and missing analysts' consensus estimates. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Bausch + Lomb News
AllArticlesVideos
BAUSCH & LOMB ALERT: Bragar Eagel & Squire, P.C. is Investigating Bausch + Lomb Corporation on Behalf of Bausch & Lomb Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·1 day ago
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Business Wire·3 days ago
Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Business Wire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bausch + Lomb stock?
Bausch + Lomb (BLCO) has a market cap of $4.3B as of June 28, 2025.
What is the P/E ratio for Bausch + Lomb stock?
The price to earnings (P/E) ratio for Bausch + Lomb (BLCO) stock is 0 as of June 28, 2025.
Does Bausch + Lomb stock pay dividends?
No, Bausch + Lomb (BLCO) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Bausch + Lomb dividend payment date?
Bausch + Lomb (BLCO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bausch + Lomb?
Bausch + Lomb (BLCO) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.